Results 191 to 200 of about 671,072 (327)

Impact of APOE ε4 Genotype Load on Cognitive Function and Lipid Metabolism in Patients With Cerebral Small Vessel Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin, Haocheng Yang, Feng Liu, Sihao Lin, Junru Hu, Jian Wang, Yulan Gou   +6 more
wiley   +1 more source

The Elephant in the Room: A Systematic Review of the Application and Effects of Psychological Treatments for Pregnant Women with Dual Pathology (Mental Health and Substance-Related Disorders). [PDF]

Int J Environ Res Public Health
Caro-Cañizares I, López Carpintero N, Carmona-Camacho R.   +2 more
europepmc   +1 more source

A review of pharmacogenetic studies of substance-related disorders. [PDF]

Drug Alcohol Depend, 2015
Jones JD, Comer SD.
europepmc   +1 more source

Prospects for reconsolidation-focused treatments of substance use and anxiety-related disorders

, 2019
Daniel J. Paulus, Sunjeev K. Kamboj, Ravi Das, Michael E. Saladin   +3 more
openalex   +2 more sources

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source

Reasons for High Emergency Department Use Among Patients With Common Mental Disorders or Substance-Related Disorders. [PDF]

Healthc Policy
Dion KM, Ferland F, Farand L, Gauvin L, Fleury MJ.   +4 more
europepmc   +1 more source

Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. [PDF]

Curr Vasc Pharmacol, 2016
Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q.   +10 more
europepmc   +1 more source

Early-Onset Depressive Disorders, Related Mental Health Disorders and Substance Use-A Prospective, Longitudinal Study of Finnish Twins Born 1983-1987

, 2010
Elina Sihvola
openalex   +1 more source

Trends in Substance Use Disorder-related Admissions at a Safety-net Hospital, 2008 – 2020

, 2021
Amber R. Lindsay, Riley D. Shearer, Gavin Bart, Tyler N. A. Winkelman   +3 more
openalex   +2 more sources

The MMP‐9/TIMP‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS ...
Ivan Pavlovic, Ida Erngren, Kim Kultima, Anders Larsson, Malin Müller, Anna Wiberg, Joachim Burman   +6 more
wiley   +1 more source